We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Clinical Data

This section contains clinical trial results and is organized by indication - Venous Leg Ulcer and Diabetic Foot Ulcer.

Venous Leg Ulcer Indication

Indicated for use along with standard compression therapy in venous ulcers of at least 1 month in duration that have not adequately responded to conventional ulcer therapy.

Diabetic Foot Ulcer Indication

Apligraf® is also indicated for use with conventional diabetic foot ulcer care for the treatment of full-thickness neuropathic diabetic foot ulcers of greater than three weeks duration which extend through the dermis but without tendon, muscle, capsule or bone exposure.